Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories

April 20, 2011 By Bio-Medicine.Org

BUFFALO, N.Y., April 20, 2011 /PRNewswire/ —  Kinex
Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced
today the execution of a license agreement granting Hanmi
Pharmaceuticals exclusive rights to their lead compound, KX01, for
all oncology indications in selected Asian Territories.

KX01 (KX2-391) is a potent, orally available small molecule Src
kinase/pretubulin dual mechanism inhibitor discovered and currently
developed by Kinex Pharmaceuticals using its proprietary technology
platforms Mimetica™ and Opal™. KX01 differentiates
itself as an inhibitor that targets the kinase substrate pocket and
therefore, offers an excellent efficacy as well as safety profile.
The composition of matter of KX01 is covered by issued patents.

KX01 has been shown to be very effective against a broad range
of cancers in both in vitro experiments and in animal cancer
models. Importantly, the compound has synergistic/additive
activities with most first line chemotherapeutic agents. A
completed Phase I study, in patients with end-stage cancer, showed
a desirable safety profile and clinical response in approximately
25% of the patients. Clinical data support either once or twice
daily dosing. Phase II studies are ongoing.  

Under the terms of the agreement, Hanmi Pharmaceuticals will
acquire the rights to the development and commercialization of KX01
for all oncology indications in certain Asian territories,
including Korea, greater China and some Southeast Asian Countries.
Japan, India, Australia and New Zealand are not included in this
agreement. 

Hanmi Pharmaceuticals will assume all development responsibility
and associated costs in the licensed territories and will
participate with Kinex Pharmaceuticals on Phase III global
registration studies. Hanmi Pharmaceuticals will also provide Kinex
Pharmaceuticals with an up-front payment, milestone payments and
royalties. A joint development team will be establis

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech